Bremelanotide vs PT-141
Head-to-head comparison of Bremelanotide (Bremelanotide (PT-141), cyclic melanocortin receptor agonist) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Bremelanotide | PT-141 |
|---|---|---|
| Category | Sexual Health | Performance |
| Full Name | Bremelanotide (PT-141), cyclic melanocortin receptor agonist | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 1025.2 Da | 1,025.2 Da |
| Half-Life | about 2.7 h | ~2.7 hours |
| Amino Acids | 7 | 7 |
| Typical Dose | 1.75 mg | 1.75 mg |
| Route | Subcutaneous | SC |
| Purity | ≥98% | — |
| Studies Count | 200 | 178 |
| Research Status | Clinical | FDA Approved |
Bremelanotide Benefits
- ✓increases sexual desire
- ✓supports arousal
- ✓may improve erectile response
- ✓on-demand use
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
Bremelanotide Dosing
1.75 mg subcutaneous PRN|administer about 45 minutes before activity|max 1 dose per 24 hours
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
Bremelanotide Side Effects
- ⚠nausea
- ⚠flushing
- ⚠headache
- ⚠transient blood pressure increase
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
Bremelanotide
Human studies and approval data support meaningful effects on sexual desire in women, with a central mechanism involving melanocortin signaling. It is one of the most clinically relevant peptides in this category and is commonly used as the reference compound for PT-141-type research.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.